Key Highlights
- Diluted loss per share of USD 0.82 was narrower than the consensus estimate of a USD 0.88 loss.
- Revenue fell to USD 0.5 million from USD 41.9 million, well below the consensus estimate of USD 16.93 million.
- Cash and marketable securities totaled USD 558.9 million, down from USD 685.4 million at the end of 2025.
- Research and development expense dropped to USD 46.9 million from USD 64.7 million, and general and administrative expense fell 40%.
Arvinas, Inc. (NASDAQ:ARVN) reported a third quarter 2026 net loss of USD 53.9 million, or USD 0.82 per diluted share, compared with a net loss of USD 35.1 million, or USD 0.48 per share, a year earlier. The loss per share was narrower than a consensus estimate of a USD 0.88 loss. Revenue of USD 0.5 million, all of it sales-based royalties under the Rigel license agreement, was far below a consensus estimate of USD 16.93 million and the USD 41.9 million booked in the prior year quarter.
Spending Cuts Offset the Revenue Drop
The prior year revenue figure included USD 20.6 million under the original vepdegestrant collaboration with Pfizer and a USD 20.0 million development milestone tied to the Novartis license. The Pfizer revenue did not recur after all remaining deferred revenue was recognized in the second quarter of 2026, when the Rigel agreement was signed. Research and Development expense fell USD 17.8 million to USD 46.9 million, with program spending on vepdegestrant down USD 14.2 million, partly offset by higher spending on ARV-027, ARV-6723 and ARV-393 of USD 4.6 million, USD 3.3 million and USD 3.2 million. General and administrative expense declined USD 8.4 million to USD 12.6 million. Loss from operations widened to USD 59.1 million from USD 43.8 million, and interest and other income slipped to USD 5.4 million from USD 9.0 million.
Cash Runway and Pipeline Timeline
Cash, cash equivalents, restricted cash and marketable securities stood at USD 558.9 million on September 30, 2026. Cash used in operations over nine months was USD 123.0 million, net of USD 35.0 million received under the Rigel agreement. Management said current resources fund planned operating and Capital expenses into the second half of 2028. Chief Executive Officer Randy Teel said the company is directing spending toward programs backed by early evidence and is entering a period of clinical milestones for its BCL6, polyQ-AR and HPK1 degraders. Dosing began in a Phase 1/2 trial of ARV-6723, an oral HPK1 degrader, and additional ARV-102 biomarker data in Parkinson disease patients were shown at a movement disorders congress.
Dated Pipeline Events Against the Cash Position
Cash, restricted cash and marketable securities of USD 558.9 million compare with USD 685.4 million at year end, a USD 126.5 million decline, while total liabilities fell to USD 93.7 million from USD 284.0 million. Initial ARV-393 dose escalation data were submitted for the American Society of Hematology meeting on December 12 to 15, 2026, with additional monotherapy data and initial glofitamab combination data scheduled for mid-2027. ARV-027 healthy volunteer data are scheduled for the first half of 2027, and initial ARV-6723 monotherapy data for the second half of 2027. Clinical trial applications for an ARV-102 Phase 1b study in progressive supranuclear palsy are scheduled for the European Union in the fourth quarter of 2026 and the United Kingdom in the first quarter of 2027.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...